Latest news:  New publication: EC-70124 exerts potent activity in acute myeloid leukemia…  [ read more ]

News & Press Releases [ subscribe for updates ]

Media (spanish)

EC-70124 acts as dual FLT3 PIM inhibitor
and exerts potent activity in acute myeloid leukemia


January 17th, 2018 - Oviedo (Spain)

The research, focuses on preclinical models bearing FLT3 mutations, and its blocking by EC-70124, a multi-kinase inhibitor previously characterized in solid tumor models…


New Oncotarget publication: EntreChem's mithralog EC-8042 targets sarcoma cancer stem cells by inhibiting SP1 transcription factor

May 2nd, 2016 - Oviedo (Spain)

The results of a collaborative research from EntreChem SL and the Hospital Universitario Central de Asturias, HUCA (Oviedo, Spain), focused on a new strategy for treating sarcomas, especially targeting the tumor initiating cells…


EntreChem's mithralog EC-8042 promising activity for Ewing sarcoma,
published in Clinical Cancer Research


April 4th, 2016 - Oviedo (Spain)

The research, directed by Patrick Grohar, Ph.D. M.D. screened a panel of mithralogs to establish their ability to inhibit EWS-FLI1 in Ewing sarcoma cell line. Both mithramycin and EC-8042 suppress the activity of EWS-FLI1…




more news & media

La biotecnología tira del carro investigador

07-10-2013, La Nueva España

La molécula EC-70124 de EntreChem muestra actividad por vía oral en cáncer de próstata

20-05-2013, El Comercio

Los grupos Alimerka y Orejas refuerzan sus posiciones en el laboratorio Entrechem

22-06-2012, La Nueva España

Antitumorales ‘made in’ Asturias

07-07-2011, El País

Tras la química combinatoria, análogos al poder

21-06-2011, Diario Médico

EntreChem necesita 5 millones para curar el tumor cerebral

31-05-2011, Expansión